Table 2.
Baseline clinical characteristics after the propensity score-matched cohorts
| Non-ESRD | ESRD | p value | |
|---|---|---|---|
| Patients | 100 (50.0) | 100 (50.0) | |
| Age (years) | 70.2 ± 11.8 | 71.0 ± 9.5 | 0.58 |
| Follow-up intervals - months | 26.6 (10.1,40.2) | 19.2 (7.4,35.9) | 0.10 |
| Male sex | 60 (60.0) | 62 (62.0) | 0.78 |
| Current smoker | 21 (21.0) | 13 (13.0) | 0.13 |
| CVD history | 35 (35.0) | 39 (39.0) | 0.56 |
| Stroke history | 23 (23.0) | 27 (27.0) | 0.51 |
| HTN | 76 (76.0) | 70 (70.0) | 0.34 |
| DM | 78 (78.0) | 86 (86.0) | 0.14 |
| Hyperlipidemia | 55 (55.0) | 58 (58.0) | 0.67 |
| Previous statin | 50 (50.0) | 49 (49.0) | 0.89 |
| Previous antiplatelet | 62 (62.0) | 63 (63.0) | 0.89 |
| Rutherford classification | 0.15 | ||
|
3 4 5 6 |
23 (23.0) 5 (5.0) 50 (50.0) 22 (22.0) |
12 (12.0) 5 (5.0) 64 (64.0) 10 (10.0) |
|
| Previous ipsilateral intervention | 15 (15.0) | 13 (13.0) | 0.68 |
| Previous contralateral intervention | 21 (21.0) | 22 (22.0) | 0.86 |
| Intervention left side | 47 (47.0) | 54 (54.0) | 0.32 |
| Multilevel disease | 32 (32.0) | 33 (33.0) | 0.88 |
| Aortoiliac occlusive disease | 25 (25.0) | 16 (16.0) | 0.12 |
| Femoropopliteal lesion | 63 (63.0) | 62 (62.0) | 0.88 |
| Infrapopliteal lesion | 46 (46.0) | 56 (56.0) | 0.16 |
| Lesion length (mm) | 149.8 ± 107.1 | 157.9 ± 106.5 | 0.59 |
| TASC II classification of aorto-iliac disease (n = 41) | 0.72 | ||
|
A B C D |
11 (44.0) 8 (32.0) 1 (4.0) 5 (20.0) |
7 (43.8) 7 (43.8) 0 (0) 2 (12.5) |
|
| TASC II Classification of femoral popliteal disease (n = 125) | 0.80 | ||
|
A B C D |
10 (15.9) 31 (49.2) 6 (9.5) 16 (25.4) |
7 (11.3) 33 (53.2) 8 (12.9) 14 (22.6) |
|
| GLASS score (n = 148) | 0.70 | ||
|
Stage 1 Stage 2 Stage 3 |
13 (19.4) 22 (32.8) 32 (47.8) |
14 (17.3) 32 (39.5) 35 (43.2) |
|
| Original Bollinger score | 43 (26.5, 55) | 39 (28,51) | 0.53 |
| Extended version of the Bollinger score | 88 (51.5, 125.75) | 93 (54.5, 118.0) | 0.91 |
| Intervention successful rate | 94 (94.0) | 95 (95.0) | 0.76 |
| Type of intervention | 0.08 | ||
|
PTA only Stent |
67 (67.0) 33 (33.0) |
78 (78.0) 22 (22.0) |
Values are n (%), mean ± SD or median (interquartile range). CVD, cardiovascular disease; DM, diabetic mellitus; ESRD, end-stage renal disease; GLASS, global limb anatomic staging system; HTN, hypertension; SD, standard deviation; PTA, percutaneous transluminal angioplasty; TASC, Trans-Atlantic Inter-Society Consensus